Page 115 - 《中国药房》2021年第4期

Investigators et al：N Engl J Med 2010；363（26）：2499- [14] SIMMONS B，WYSOKINSKI W，SAADIQ RA，et al. Ef-
2510[J]. J Vasc Nurs，2010. DOI：10.1016/j.jvn.2011.03.002. ficacy and safety of rivaroxaban compared to enoxaparin
[ 6 ] WEITZ JI，LENSING AWA，PRINS MH，et al. Rivaroxa- in treatment of cancer-associated venous thromboembo-
ban or aspirin for extended treatment of venous thrombo- lism[J]. Eur J Haematol，2018. DOI：10.1111/ejh.13074.
embolism[J]. N Engl J Med，2017，376（13）：1211-1222. [15] WYSOKINSKI WE，HOUGHTON DE，CASANEGRAAI，
[ 7 ] KHORANA AA，SOFF GA，KAKKAR AK，et al. Riva- et al. Comparison of apixaban to rivaroxaban and enoxapa-
roxaban for thromboprophylaxis in high-risk ambulatory rin in acute cancer-associated venous thromboembo-
patients with cancer[J]. N Engl J Med，2019，380（8）： lism[J]. Am J Hematol，2019，94（11）：1185-1192.
720-728. [16] CONNORS JM. Prophylaxis against venous thromboem-
[ 8 ] NICKLAUS MD，LUDWIG SL，KETTLE JK. Recur- bolism in ambulatory patients with cancer[J]. N Engl J
rence of malignancy-associated venous thromboembolism Med，2014，370（26）：2515-2519.
among patients treated with rivaroxaban compared to [17] PRANDONI P，LENSING AW，PICCIOLI A，et al. Recur-
enoxaparin[J]. J Oncol Pharm Pract，2018，24（3）：185- rent venous thromboembolism and bleeding complica-
189. tions during anticoagulant treatment in patients with can-
[ 9 ] KEARON C，AKL EA，ORNELAS J，et al. Antithrombo- cer and venous thrombosis[J]. Blood，2002，100（10）：
tic therapy for VTE disease：CHEST guideline and expert 3484-3488.
panel report[J]. Chest，2016，149（2）：315-352. [18] WANG Y，WANG M，NI Y，et al. Direct oral anticoagu-
[10] STEWART LA，CLARKE M，ROVERS M，et al. Pre- lants for thromboprophylaxis in ambulatory patients with
ferred reporting items for a systematic review and me- cancer[J]. Hematology，2020，25（1）：63-70.
ta-analysis of individual participant data：the PRISMA- [19] FUENTES HE，MCBANE RD 2ND，WYSOKINSKI WE，
IPD statement[J]. JAMA，2015，313（16）：1657-1665. et al. Direct oral factor xa inhibitors for the treatment of
[11] WELLS GA，TUGWELL P，O’CONNELL D，et al. The acute cancer-associated venous thromboembolism：a sys-
Newcastle-Ottawa Scale（NOS）for assessing the quality tematic review and network meta-analysis[J]. Mayo Clin
of nonrandomized studies in meta-analyses[EB/OL].[2020- Proc，2019，94（12）：2444-2454.
04-10]. http：//www.ohri.ca/programs/clinical_epidemiolo- [20] LI A，KUDERER NM，GARCIA DA，et al. Direct oral an-
gy/oxford.asp. ticoagulant for the prevention of thrombosis in ambulato-
[12] SIGNORELLI JR，GANDHI AS. Evaluation of rivaroxa- ry patients with cancer：a systematic review and meta-anal-
ban use in patients with gynecologic malignancies at an ysis[J]. J Thromb Haemost，2019，17（12）：2141-2151.
academic medical center：a pilot study[J]. J Oncol Pharm [21] XING J，YIN X，CHEN D. Rivaroxaban versus enoxapa-
Pract，2019，25（2）：362-368. rin for the prevention of recurrent venous thromboembo-
[13] ALZGHARI SK，SEAGO SE，GARZA JE，et al. Retro- lism in patients with cancer：a meta-analysis[J]. Medicine
spective comparison of low molecular weight heparin vs. （Baltimore），2018. DOI：10.1097/MD.0000000000011-
warfarin vs. oral Xa inhibitors for the prevention of recur- 384.
rent venous thromboembolism in oncology patients：the （收稿日期：2020-07-24 修回日期：2021-01-11）
Re-CLOT study[J]. J Oncol Pharm Pract，2017，24（7）： （编辑：陈 宏）
494-500.

《中国药房》杂志——RCCSE中国核心学术期刊，欢迎投稿、订阅

中国药房 2021年第32卷第4期 China Pharmacy 2021 Vol. 32 No. 4 ·489 ·